540 related articles for article (PubMed ID: 20508896)
1. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.
Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
Thromb Haemost; 2010 Aug; 104(2):279-86. PubMed ID: 20508896
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249
[TBL] [Abstract][Full Text] [Related]
3. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
[TBL] [Abstract][Full Text] [Related]
4. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
[TBL] [Abstract][Full Text] [Related]
5. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
[TBL] [Abstract][Full Text] [Related]
6. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Breet NJ; van Werkum JW; Bouman HJ; Kelder JC; Harmsze AM; Hackeng CM; ten Berg JM
Heart; 2011 Jun; 97(12):983-90. PubMed ID: 21478385
[TBL] [Abstract][Full Text] [Related]
7. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.
Paniccia R; Antonucci E; Maggini N; Miranda M; Gori AM; Marcucci R; Giusti B; Balzi D; Prisco D; Abbate R
Thromb Haemost; 2010 Aug; 104(2):287-92. PubMed ID: 20458439
[TBL] [Abstract][Full Text] [Related]
8. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
[TBL] [Abstract][Full Text] [Related]
9. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment.
Bernlochner I; Steinhubl S; Braun S; Morath T; Jaitner J; Stegherr J; Mehilli J; von Beckerath N; Schömig A; Kastrati A; Sibbing D
Thromb Haemost; 2010 Dec; 104(6):1193-200. PubMed ID: 20838744
[TBL] [Abstract][Full Text] [Related]
10. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
[TBL] [Abstract][Full Text] [Related]
11. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
12. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
[TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.
Gurbel PA; Antonino MJ; Bliden KP; Dichiara J; Suarez TA; Singla A; Tantry US
Platelets; 2008 Dec; 19(8):595-604. PubMed ID: 19012177
[TBL] [Abstract][Full Text] [Related]
14. Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management.
Cuisset T; Quilici J; Fugon L; Cohen W; Roux P; Gaborit B; Molines L; Fourcade L; Bonnet JL; Carrieri P
Arch Cardiovasc Dis; 2011 May; 104(5):306-12. PubMed ID: 21693367
[TBL] [Abstract][Full Text] [Related]
15. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel.
Bonello L; Mancini J; Pansieri M; Maillard L; Rossi P; Collet F; Jouve B; Wittenberg O; Laine M; Michelet P; Bessereau J; Lemesle G; Dignat-George F; Paganelli F; Camoin-Jau L
J Thromb Haemost; 2012 Oct; 10(10):1999-2005. PubMed ID: 22863374
[TBL] [Abstract][Full Text] [Related]
16. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
[TBL] [Abstract][Full Text] [Related]
17. Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting.
Huczek Z; Filipiak KJ; Kochman J; Michalak M; Roik M; Grabowski M; Opolski G
Platelets; 2011; 22(7):521-9. PubMed ID: 21443410
[TBL] [Abstract][Full Text] [Related]
18. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
[TBL] [Abstract][Full Text] [Related]
20. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]